AN UNBIASED VIEW OF GR 113808

quinupristin/dalfopristin will increase the degree or influence of lemborexant by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Stay clear of coadministration of lemborexant with moderate or powerful CYP3A inhibitors.2 The 50 percent-lifetime of quinupristin and its metabolites is roughly three hours